- FDA rejects Hengrui-Elevar liver cancer drug combo for third timeFor the third time in about two years, the FDA has cited manufacturing deficiencies in rejecting a drug combination from Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics intended to treat th…Endpoints · 17d ago↗ source
- CDER adds 100+ new employees in a quarter for first time since late 2024The FDA's drug center hired more new employees than it lost in a quarter for the first time since the Trump administration gutted the agency's ranks in April 2025. The FDA'sEndpoints · 17d ago↗ source
- US biotechs turn secretive as they fear competition from rising Chinese industryJanine Sengstack believes she may have found the next big breakthrough in diabetes and obesity. Her company, Junevity, has searched through hundreds of genes to discover ones that, when repressed,…